A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache - I5Q-MC-CGAM

Eli Lilly and Company0 个研究点目标入组 237 人开始时间: 2016年8月22日最近更新: 2020年11月3日

适应症

试验速览

暂无简介。

•Participants (or patients) with a history of chronc cluster headache occuring without a remission period, or with remissions lasting less than 1 month for at least 1 year.
•Participants (or patients) are able to distinguish cluster headache
•attacks from other headaches.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 157
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•Current enrollment in or discontinuation within the last 30 days from, a
•clinical trial involving any investigational drug or device.
•Current use or any prior exposure to any CGRP antibody, any antibody
•to the CGRP receptor, or antibody to nerve growth factor (NGF).
•Are taking indomethacin and/or are suspected of having another
•distinct trigeminal autonomic cephalalgia
•A history of migraine variants that could implicate or could be
•confused with ischemia
•Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.
•A history or presence of other medical illness that indicates a medical problem that would preclude study participation.
•Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.
•Women who are pregnant or nursing.

发起方